Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Curr Opin Urol ; 28(1): 62-79, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29059103

RESUMO

PURPOSE OF REVIEW: The incidence of kidney cancer rises globally with the highest rates in developed countries. This demonstrates the impact of advanced diagnostic imaging but also rising prevalence of modifiable risk factors such as smoking, obesity and hypertension. A literature search was performed with focus on recent studies on risk factors related to lifestyle, medication and nutrition. Further we searched for the effect of cancer prevention strategies. RECENT FINDINGS: Overall, we included 76 studies of the past 5 years. Based on current evidence smoking tobacco, obesity and hypertension remain established risk factors for kidney cancer. Certain analgesics and consumption of processed meat have been linked to increase development of renal cell carcinoma, although data are limited. Fruits, fiber-rich vegetables, coffee and physical activity may have a protective effect against kidney cancer but causal conclusions are not yet supported. Significantly, there is an increasing evidence of inverse association between moderate alcohol consumption. SUMMARY: Overall evidence confirms an effective way to prevent the risk of kidney cancer is maintaining a healthy weight and avoid smoking. State policies should further ensure strategies to raise public awareness and support to adopt healthy lifestyles.


Assuntos
Carcinoma de Células Renais/prevenção & controle , Neoplasias Renais/prevenção & controle , Estilo de Vida , Recidiva Local de Neoplasia/prevenção & controle , Analgésicos/efeitos adversos , Anti-Hipertensivos/efeitos adversos , Carcinoma de Células Renais/dietoterapia , Carcinoma de Células Renais/epidemiologia , Carcinoma de Células Renais/patologia , Exercício Físico/fisiologia , Comportamento Alimentar/fisiologia , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/epidemiologia , Incidência , Rim/efeitos dos fármacos , Rim/patologia , Neoplasias Renais/dietoterapia , Neoplasias Renais/epidemiologia , Neoplasias Renais/patologia , Recidiva Local de Neoplasia/dietoterapia , Recidiva Local de Neoplasia/epidemiologia , Recidiva Local de Neoplasia/patologia , Obesidade/epidemiologia , Prevalência , Fatores de Risco , Comportamento de Redução do Risco , Fumar/epidemiologia
2.
Future Oncol ; 13(15): 1323-1332, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28485672

RESUMO

AIM: To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma. PATIENTS & METHODS: We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31 October 2014 in 135 metastatic renal cell carcinoma patients using the US Oncology Network database. RESULTS: Overall, 86.7% had clear cell histology, 57.8% had stage III/IV disease at diagnosis and 55.6% were poor risk by Heng criteria. Median treatment duration was 4.6 months (range: 0.03-35.49); 80.7% initiated axitinib at 5 mg/day twice daily, and 67.4% maintained this dose. Overall, 77.8% discontinued treatment, mainly due to disease progression (50.5%) and toxicity (21.9%). CONCLUSION: Axitinib usage patterns were consistent with the National Comprehensive Cancer Network Guidelines®. Ease of use among community oncologists and patient tolerance are key features of axitinib.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma de Células Renais/dietoterapia , Centros Comunitários de Saúde/estatística & dados numéricos , Imidazóis/uso terapêutico , Indazóis/uso terapêutico , Neoplasias Renais/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Axitinibe , Carcinoma de Células Renais/patologia , Centros Comunitários de Saúde/organização & administração , Feminino , Humanos , Neoplasias Renais/patologia , Masculino , Oncologia/organização & administração , Oncologia/estatística & dados numéricos , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Estados Unidos
3.
Int J Cancer ; 136(5): 1104-16, 2015 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-24978482

RESUMO

Hypertension is an established risk factor for renal cell cancer (RCC). The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and is closely linked to hypertension. RAAS additionally influences homeostasis of electrolytes (e.g. sodium and potassium) and fluid. We investigated single nucleotide polymorphisms (SNPs) in RAAS and their interactions with hypertension and intakes of sodium, potassium and fluid regarding RCC risk in the Netherlands Cohort Study (NLCS), which was initiated in 1986 and included 120,852 participants aged 55 to 69 years. Diet and lifestyle were assessed by questionnaires and toenail clippings were collected. Genotyping of toenail DNA was performed using the SEQUENOM® MassARRAY® platform for a literature-based selection of 13 candidate SNPs in seven key RAAS genes. After 20.3 years of follow-up, Cox regression analyses were conducted using a case-cohort approach including 3,583 subcohort members and 503 RCC cases. Two SNPs in AGTR1 were associated with RCC risk. AGTR1_rs1492078 (AA vs. GG) decreased RCC risk [hazard ratio (HR) (95% confidence interval (CI)): 0.70(0.49-1.00)], whereas AGTR1_rs5186 (CC vs. AA) increased RCC risk [HR(95%CI): 1.49(1.08-2.05)]. Associations were stronger in participants with hypertension. The RCC risk for AGT_rs3889728 (AG + AA vs. GG) was modified by hypertension (p interaction = 0.039). SNP-diet interactions were not significant, although HRs suggested interaction between SNPs in ACE and sodium intake. SNPs in AGTR1 and AGT influenced RCC susceptibility, and their effects were modified by hypertension. Sodium intake was differentially associated with RCC risk across genotypes of several SNPs, yet some analyses had probably inadequate power to show significant interaction. Results suggest that RAAS may be a candidate pathway in RCC etiology.


Assuntos
Carcinoma de Células Renais/etiologia , Hipertensão/complicações , Neoplasias Renais/etiologia , Polimorfismo Genético/genética , Potássio na Dieta/administração & dosagem , Sistema Renina-Angiotensina/genética , Sódio na Dieta/administração & dosagem , Idoso , Angiotensinogênio/genética , Carcinoma de Células Renais/dietoterapia , Carcinoma de Células Renais/patologia , DNA de Neoplasias/genética , Feminino , Seguimentos , Interação Gene-Ambiente , Humanos , Hipertensão/dietoterapia , Hipertensão/genética , Neoplasias Renais/dietoterapia , Neoplasias Renais/patologia , Masculino , Pessoa de Meia-Idade , Peptidil Dipeptidase A/genética , Reação em Cadeia da Polimerase , Prognóstico , Estudos Prospectivos , Receptor Tipo 1 de Angiotensina/genética
4.
Nutrients ; 16(9)2024 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-38732632

RESUMO

Nutritional therapy (NT) based on a controlled protein intake represents a cornerstone in managing chronic kidney disease (CKD). However, if a CKD patient is at the same time affected by cancer, oncologists and nutritionists tend to suggest a dietary regimen based on high protein intake to avoid catabolism and malnutrition. International guidelines are not clear when we consider onco-nephrological patients and, as a consequence, no clinical shared strategy is currently applied in clinical practice. In particular, no precise nutritional management is established in nephrectomized patients for renal cell carcinoma (RCC), a specific oncological cohort of patients whose sudden kidney removal forces the remnant one to start a compensatory mechanism of adaptive hyperfiltration. Our study aimed to investigate the efficacy of a low-normal-protein high-calorie (LNPHC) diet based on a Mediterranean model in a consecutive cohort of nephrectomized RCC patients using an integrated nephrologist and nutritionist approach. A consecutive cohort of 40 nephrectomized RCC adult (age > 18) patients who were screened for malnutrition (malnutrition screening tool, MST < 2) were enrolled in a tertiary institution between 2020 and 2022 after signing a specific informed consent form. Each patient underwent an initial nephrological and nutritional evaluation and was subsequently subjected to a conventional CKD LNPHC diet integrated with aproteic foods (0.8 g/Kg/die: calories: 30-35 kcal per kg body weight/die) for a period of 6 months (±2 months). The diet was structured after considering eGFR (CKD-EPI 2021 creatinine formula), comorbidities, and nutritional status. MST, body mass index (BMI), phase angle (PA), fat mass percentage (FM%), fat-free mass index (FFMI), body cell mass index (BCMI), extracellular/intracellular water ratio (ECW/ICW), extracellular matrix/body cell mass ratio (ECM/BCM), waist/hip circumference ratio (WHC), lab test exams, and clinical variables were examined at baseline and after the study period. Our results clearly highlighted that the LNPHC diet was able to significantly improve several nutritional parameters, avoiding malnutrition and catabolism. In particular, the LNPHC diet preserved the BCM index (delta on median, ΔM + 0.3 kg/m2) and reduced the ECM/BCM ratio (ΔM - 0.03 *), with a significant reduction in the ECW/ICW ratio (ΔM - 0.02 *), all while increasing TBW (ΔM + 2.3% *). The LNPHC diet was able to preserve FFM while simultaneously depleting FM and, moreover, it led to a significant reduction in urea (ΔM - 11 mg/dL **). In conclusion, the LNPHC diet represents a new important therapeutic strategy that should be considered when treating onco-nephrological patients with solitary kidney due to renal cancer.


Assuntos
Carcinoma de Células Renais , Neoplasias Renais , Nefrectomia , Estado Nutricional , Humanos , Masculino , Neoplasias Renais/cirurgia , Neoplasias Renais/dietoterapia , Neoplasias Renais/complicações , Feminino , Pessoa de Meia-Idade , Idoso , Carcinoma de Células Renais/cirurgia , Carcinoma de Células Renais/dietoterapia , Desnutrição/etiologia , Rim/fisiopatologia , Dieta Mediterrânea , Resultado do Tratamento , Insuficiência Renal Crônica/dietoterapia , Insuficiência Renal Crônica/terapia
5.
Urol Oncol ; 39(10): 623-630, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34253447

RESUMO

PURPOSE: To perform a systematic review and meta-analysis of the Prognostic Nutritional Index (PNI) as a prognostic factor for renal cell carcinoma (RCC). MATERIALS AND METHODS: Eligible studies that evaluated the prognostic impact of pretreatment PNI in RCC patients were identified by comprehensive searching the electronic databases PubMed, Cochrane Central Search library, and EMBASE. The end points were overall/cancer-specific survival (OS/CSS) and recurrence-free/disease-free survival (RFS/DFS). Meta-analysis using random-effects models was performed to calculate hazard ratios (HRs) with 95 % confidence intervals (CIs). RESULTS: In total, 9 retrospective, observational, case-control studies involving 5,976 patients were included for final analysis. Eight studies evaluated OS/CSS, and 5 evaluated RFS/DFS. Our results showed that lower PNI was significantly associated with unfavorable OS/CSS (HR = 1.68, 95% CI 1.44-1.96, P < 0.001, I2 = 9.2%, P = 0.359) and RFS/DFS (HR = 1.98, 95% CI 1.57-2.50, P < 0.001, I2 = 18.2%, P = 0.299) in patients with RCC. Subgroup and meta-regression analysis based on ethnicity, study sample size, presence of metastasis, PNI cut-off value, Newcastle-Ottawa quality assessment scale (NOS) score, and gender ratio all showed that lower PNI was associated with poorer OS/CSS and RFS/DFS. Funnel plots and Egger's tests indicated significant publication bias in OS/CSS (P = 0.001), but not in RFS/DFS (P = 0.757). CONCLUSION: This meta-analysis indicated that lower PNI was a negative prognostic factor and associated with tumor progression and poorer survival of patients with RCC. Therefore, PNI could be a potential prognostic predictor of treatment outcomes for patients with RCC.


Assuntos
Carcinoma de Células Renais/dietoterapia , Neoplasias Renais/dietoterapia , Carcinoma de Células Renais/mortalidade , Feminino , Humanos , Neoplasias Renais/mortalidade , Masculino , Avaliação Nutricional , Prognóstico , Análise de Sobrevida
6.
Oncol Rep ; 42(5): 1878-1892, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31545459

RESUMO

3D spheroids are built by heterogeneous cell types in different proliferative and metabolic states and are enriched in cancer stem cells. The main aim of the study was to investigate the usefulness of a novel metastatic renal cell carcinoma (RCC) 3D spheroid culture for in vitro cancer stem cell physiology research and drug toxicity screening. RCC cell lines, Caki­1 (skin metastasis derived) and ACHN (pleural effusion derived), were efficiently cultured in growth­factor/serum deprived, defined, StemXvivo and Nutristem medium on laminin­coated or poly­D­lysine­coated plates. In optimal 3D culture conditions, ACHN cells (StemXVivo/poly­D­lysine) formed small spheroids with remaining adherent cells of an epithelial phenotype, while Caki­1 cells (StemXVivo/laminin) formed large dark spheroids with significantly reduced cell viability in the center. In the 3D structures, expression levels of genes encoding stem transcription factors (OCT4, SOX2, NES) and RCC stem cell markers (CD105, CD133) were deregulated in comparison to these expression levels in traditional 2D culture. Sunitinib, epirubicin and doxycycline were more toxic to cells cultured in monolayers than for cells in 3D spheroids. High numbers of cells arrested in the G0/G1 phase of the cell cycle were found in spheroids under sunitinib treatment. We showed that metastatic RCC 3D spheroids supported with ECM are a useful model to determine the cancer cell growth characteristics that are not found in adherent 2D cultures. Due to the more complex architecture, spheroids may mimic in vivo micrometastases and may be more appropriate to investigate novel drug candidate responses, including the direct effects of tyrosine kinase inhibitor activity against RCC cells.


Assuntos
Biomarcadores Tumorais/genética , Carcinoma de Células Renais/genética , Técnicas de Cultura de Células/métodos , Meios de Cultura Livres de Soro/química , Resistencia a Medicamentos Antineoplásicos , Neoplasias Renais/genética , Células-Tronco Neoplásicas/química , Biomimética , Carcinoma de Células Renais/dietoterapia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Doxiciclina/farmacologia , Epirubicina/farmacologia , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Neoplasias Renais/tratamento farmacológico , Laminina/farmacologia , Metástase Neoplásica , Células-Tronco Neoplásicas/efeitos dos fármacos , Fenótipo , Esferoides Celulares/química , Esferoides Celulares/citologia , Esferoides Celulares/efeitos dos fármacos , Sunitinibe/farmacologia
7.
Immunotherapy ; 10(9): 743-752, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-30008256

RESUMO

AIM: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. METHODS: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). RESULTS: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. CONCLUSION: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.


Assuntos
Hidrolases Anidrido Ácido/genética , Antineoplásicos/uso terapêutico , Carcinoma de Células Renais/dietoterapia , Neoplasias Renais/tratamento farmacológico , Proteínas de Neoplasias/genética , Nivolumabe/uso terapêutico , Proteínas Adaptadoras de Transdução de Sinal/genética , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Renais/genética , Carcinoma de Células Renais/mortalidade , Reparo do DNA/genética , Feminino , Humanos , Neoplasias Renais/genética , Neoplasias Renais/mortalidade , Perda de Heterozigosidade , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Projetos Piloto , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento , Proteínas Supressoras de Tumor/genética
8.
Arch Physiol Biochem ; 124(1): 88-96, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28835129

RESUMO

Prunus amygdalus Batsch (almond) is a classical nutritive traditional Indian medicine. Along with nutritive with anti-oxidant properties, it is, clinically, used in the treatment of various diseases with underlying anti-oxidant mechanism. This study is an effort to scrutinise the renal protective effect of P. amygdalus Batsch or green almond (GA) seed coat extract and its underlying mechanism in animal model of Ferric nitrilotriacetate (Fe-NTA) induced renal cell carcinoma (RCC). RCC was induced in Swiss Albino Wistar rats by intraperitoneal injection of Fe-NTA. The rats were then treated with ethanolic extract of GA (25, 50 and 100 mg/kg per oral) for 22 weeks. Efficacy of GA administration was evaluated by change in biochemical, renal, macroscopical and histopathological parameters and alterations. Additionally, interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß) and inflammatory mediator including prostaglandin E2 (PGE2), nuclear factor-kappa B (NF-κB) were also observed to explore the possible mechanisms. The oral administration of GA significantly (p < .001) altered the Fe-NTA induced RCC in rats by inhibition of renal nodules, decolourisation of tissues, tumour promoter marker including thymidine 3[H] incorporation, ornithine decarboxylase, renal parameters and anti-oxidant parameters in serum. Additionally, GA treatment significantly (p < .001) down-regulated the IL-6, IL-1ß, TNF-α, inflammatory mediators PGE2 and NF-κB in a dose-dependent manner. Histopathology observation supported the renal protective effect of GA by alteration in necrosis, size of Bowman capsules and inflammatory cells. Hence, it can be concluded that GA possesses observable chemo-protective action and effect on Fe-NTA induced RCC via dual inhibition mechanism one by inhibiting free radical generation and second by inhibiting inflammation.


Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Carcinoma de Células Renais/dietoterapia , Suplementos Nutricionais/análise , Neoplasias Renais/dietoterapia , Epiderme Vegetal/química , Extratos Vegetais/uso terapêutico , Prunus dulcis/química , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacologia , Anti-Inflamatórios não Esteroides/uso terapêutico , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/química , Antineoplásicos Fitogênicos/farmacologia , Carcinoma de Células Renais/imunologia , Carcinoma de Células Renais/metabolismo , Carcinoma de Células Renais/patologia , Proliferação de Células , Suplementos Nutricionais/economia , Etnofarmacologia , Sequestradores de Radicais Livres/administração & dosagem , Sequestradores de Radicais Livres/química , Sequestradores de Radicais Livres/farmacologia , Sequestradores de Radicais Livres/uso terapêutico , Mediadores da Inflamação/sangue , Mediadores da Inflamação/metabolismo , Neoplasias Renais/imunologia , Neoplasias Renais/metabolismo , Neoplasias Renais/patologia , Fígado/imunologia , Fígado/metabolismo , Fígado/patologia , Masculino , Ayurveda , Necrose , Nozes/química , Nozes/economia , Extratos Vegetais/administração & dosagem , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Distribuição Aleatória , Ratos , Sementes/química , Carga Tumoral
9.
Aktuelle Urol ; 45(4): 281-5, 2014 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-25166608

RESUMO

Through the last decade considerations on the role of vitamins and antioxidants in the primary prevention of genitourinary tumors have changed dramatically. In spite of all efforts, the efficacy of a specific compound has not been proven so far. In consequence, recommendations to use vitamins or other supplements for the primary prevention of urological tumors should be avoided. However, there is some evidence that moderate food consumption, reduction of dairy products and an Asian or Mediterranean diet may not only prevent prostate cancer (PCA) but also harbour additional beneficial effects on general health. Although quantification of these findings may be difficult, it becomes evident that these measures will have additional synergistic effects on cardiovascular diseases. Considering the large number of PCA patients dying not cancer-related but from concomitant diseases, primary prevention in particular of PCA should always also consider the general health of the target population. More recent studies suggest a potential effect of nutritional compounds on biochemical tumour recurrence in PCA patients after definite therapy. These observations may serve as a starting point for validation within controlled clinical trials.


Assuntos
Comportamento Alimentar , Neoplasias Urológicas/dietoterapia , Neoplasias Urológicas/prevenção & controle , Carcinoma de Células Renais/dietoterapia , Carcinoma de Células Renais/etiologia , Carcinoma de Células Renais/prevenção & controle , Laticínios/efeitos adversos , Dieta Mediterrânea , Suplementos Nutricionais/efeitos adversos , Ingestão de Energia , Feminino , Humanos , Neoplasias Renais/dietoterapia , Neoplasias Renais/etiologia , Neoplasias Renais/prevenção & controle , Masculino , Necessidades Nutricionais , Neoplasias da Próstata/dietoterapia , Neoplasias da Próstata/etiologia , Neoplasias da Próstata/prevenção & controle , Fatores de Risco , Neoplasias da Bexiga Urinária/dietoterapia , Neoplasias da Bexiga Urinária/etiologia , Neoplasias da Bexiga Urinária/prevenção & controle , Neoplasias Urológicas/etiologia , Vitaminas/efeitos adversos
10.
Support Care Cancer ; 11(4): 232-5, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12673461

RESUMO

The use of nutritional supplements in the general population and in cancer patients has become very popular. These supplements are not perceived as medications and are presumed to be safe by cancer patients, who may however be at risk for hypercalcemia. We note that many of our patients who have developed symptomatic hypercalcemia were taking vitamin D, calcium, or shark cartilage supplements. We report eight cases of hypercalcemia in cancer patients seen at the Cleveland Clinic Foundation in whom these nutritional supplements may have contributed to the prevalence or severity of hypercalcemia.


Assuntos
Cálcio/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Hipercalcemia/induzido quimicamente , Neoplasias/dietoterapia , Vitamina D/efeitos adversos , Idoso , Animais , Neoplasias da Mama/complicações , Neoplasias da Mama/dietoterapia , Carcinoma de Células Renais/complicações , Carcinoma de Células Renais/dietoterapia , Carcinoma de Células Escamosas/complicações , Carcinoma de Células Escamosas/dietoterapia , Cartilagem , Neoplasias do Colo/complicações , Neoplasias do Colo/dietoterapia , Feminino , Humanos , Hipercalcemia/complicações , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/dietoterapia , Masculino , Mesotelioma/complicações , Mesotelioma/dietoterapia , Pessoa de Meia-Idade , Neoplasias Bucais/complicações , Neoplasias Bucais/dietoterapia , Mieloma Múltiplo/complicações , Mieloma Múltiplo/dietoterapia , Neoplasias/complicações , Tubarões , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA